Detected ·
Breye Therapeutics ApS
€67.5M—
Breye Therapeutics ApS, a Copenhagen-based biotech developing oral treatments for retinal diseases, closed an oversubscribed €67.5M Series A led by Mission BioCapital and Novo Holdings, with participation from Sound Bioventures, Innovestor Life Science, Ljungström family office, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital. Funds will advance danegaptide, an oral treatment for diabetic retinopathy, toward a Phase II trial planned for 2027.
- Website
- www.breye.com
- Amount
- €67 500 000 EUR
- Stage
- —
- Event
- Funding round
- Detected
- 2026-09-29 12:12:47 UTC
- Signal ID
- d617c2c3-8308-40f5-b95f-b31f04bb2c95
As the API returns it
{
"id": "d617c2c3-8308-40f5-b95f-b31f04bb2c95",
"created_at": "2026-09-29T12:12:47.884959Z",
"company_name": "Breye Therapeutics ApS",
"company_website_url": "www.breye.com",
"company_linkedin_url": "https://www.linkedin.com/company/breye-therapeutics-aps",
"event_type": "funding",
"funding_amount": 67500000,
"funding_currency": "EUR",
"funding_stage": null,
"message": "*Breye Therapeutics ApS, a Copenhagen-based biotech developing oral treatments for retinal diseases, closed an oversubscribed €67.5M Series A led by Mission BioCapital and Novo Holdings, with participation from Sound Bioventures, Innovestor Life Science, Ljungström family office, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital. Funds will advance danegaptide, an oral treatment for diabetic retinopathy, toward a Phase II trial planned for 2027.*"
}